Matrix Metalloproteinases As Novel Biomarkers and Potential Therapeutic Targets in Human Cancer

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2009 Sep 10

PMID 19738110

Citations 335

Authors

Roopali Roy

Jiang Yang

Marsha A Moses

Affiliations

Soon will be listed here.

Abstract

The matrix metalloproteinase (MMP) family of enzymes is comprised of critically important extracellular matrix remodeling proteases whose activity has been implicated in a number of key normal and pathologic processes. The latter include tumor growth, progression, and metastasis as well as the dysregulated angiogenesis that is associated with these events. As a result, these proteases have come to represent important therapeutic and diagnostic targets for the treatment and detection of human cancers. In this review, we summarize the literature that establishes these enzymes as important clinical targets, discuss the complexity surrounding their choice as such, and chronicle the development strategies and outcomes of their clinical testing to date. The status of the MMP inhibitors currently in US Food and Drug Administration approved clinical trials is presented and reviewed. We also discuss the more recent and successful targeting of this enzyme family as diagnostic and prognostic predictors of human cancer, its status, and its stage. This analysis includes a wide variety of human cancers and a number of human sample types including tissue, plasma, serum, and urine.

Citing Articles

A versatile platform based on matrix metalloproteinase-sensitive peptides for novel diagnostic and therapeutic strategies in arthritis.

Li M, Deng T, Chen Q, Jiang S, Li H, Li J Bioact Mater. 2025; 47:100-120.

PMID: 39897588 PMC: 11787566. DOI: 10.1016/j.bioactmat.2025.01.011.

Breast Cancer-Derived Extracellular Vesicles Modulate the Cytoplasmic and Cytoskeletal Dynamics of Blood-Brain Barrier Endothelial Cells.

Busatto S, Song T, Kim H, Hallinan C, Lombardo M, Stemmer-Rachamimov A J Extracell Vesicles. 2025; 14(1):e70038.

PMID: 39868462 PMC: 11770372. DOI: 10.1002/jev2.70038.

Targeting Invasion: The Role of MMP-2 and MMP-9 Inhibition in Colorectal Cancer Therapy.

Shoari A, Ashja Ardalan A, Dimesa A, Coban M Biomolecules. 2025; 15(1).

PMID: 39858430 PMC: 11762759. DOI: 10.3390/biom15010035.

Emerging insights in senescence: pathways from preclinical models to therapeutic innovations.

Mansfield L, Ramponi V, Gupta K, Stevenson T, Mathew A, Barinda A NPJ Aging. 2024; 10(1):53.

PMID: 39578455 PMC: 11584693. DOI: 10.1038/s41514-024-00181-1.

SERPING1 Reduces Cell Migration via ERK-MMP2-MMP-9 Cascade in Sorafenib- Resistant Hepatocellular Carcinoma.

Hsieh C, Wu Y, Chen Y, Wang C, Li C, Liu I Environ Toxicol. 2024; 40(2):318-327.

PMID: 39474998 PMC: 11726270. DOI: 10.1002/tox.24434.

References

Saghatelian A, Jessani N, Joseph A, Humphrey M, Cravatt B . Activity-based probes for the proteomic profiling of metalloproteases. Proc Natl Acad Sci U S A. 2004; 101(27):10000-5. PMC: 454150. DOI: 10.1073/pnas.0402784101. View

Fritzsche F, Jung M, Xu C, Rabien A, Schicktanz H, Stephan C . ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis. Virchows Arch. 2006; 449(6):628-36. DOI: 10.1007/s00428-006-0315-1. View

Yang W, Arii S, Mori A, Onodera H, Imamura M . Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer. 2001; 91(7):1277-83. View

Kamat A, Fletcher M, Gruman L, Mueller P, Lopez A, Landen Jr C . The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res. 2006; 12(6):1707-14. PMC: 3202606. DOI: 10.1158/1078-0432.CCR-05-2338. View

LAmoreaux W, Fitzgerald M, Reiner A, Hasty K, Charles S . Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res. 1998; 55(1):29-42. DOI: 10.1006/mvre.1997.2056. View

Xu J, Rodriguez D, Petitclerc E, Kim J, Hangai M, Moon Y . Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol. 2001; 154(5):1069-79. PMC: 2196184. DOI: 10.1083/jcb.200103111. View

Jung K, Laube C, Lein M, Lichtinghagen R, Tschesche H, Schnorr D . Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin Chem. 1998; 44(5):1060-2. View

Edwards D, Handsley M, Pennington C . The ADAM metalloproteinases. Mol Aspects Med. 2008; 29(5):258-89. PMC: 7112278. DOI: 10.1016/j.mam.2008.08.001. View

Eissa S, Swellam M, el-Mosallamy H, Mourad M, Hamdy N, Kamel K . Diagnostic value of urinary molecular markers in bladder cancer. Anticancer Res. 2003; 23(5b):4347-55. View

10.

Su L, Zhou W, Park S, Wain J, Lynch T, Liu G . Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2005; 14(3):567-70. DOI: 10.1158/1055-9965.EPI-04-0482. View

11.

Moses M, Wiederschain D, Loughlin K, Zurakowski D, LAMB C, Freeman M . Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998; 58(7):1395-9. View

12.

Bergers G, Javaherian K, Lo K, Folkman J, Hanahan D . Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 1999; 284(5415):808-12. DOI: 10.1126/science.284.5415.808. View

13.

Dong Z, Kumar R, Yang X, Fidler I . Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell. 1997; 88(6):801-10. DOI: 10.1016/s0092-8674(00)81926-1. View

14.

Friedberg M, Glantz M, Klempner M, Cole B, Perides G . Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer. 1998; 82(5):923-30. DOI: 10.1002/(sici)1097-0142(19980301)82:5<923::aid-cncr18>3.0.co;2-2. View

15.

Balbin M, Fueyo A, Tester A, Pendas A, Pitiot A, Astudillo A . Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet. 2003; 35(3):252-7. DOI: 10.1038/ng1249. View

16.

Bode W, Maskos K . Structural studies on MMPs and TIMPs. Methods Mol Biol. 2001; 151:45-77. View

17.

Sapadin A, Fleischmajer R . Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006; 54(2):258-65. DOI: 10.1016/j.jaad.2005.10.004. View

18.

Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V . Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol. 2000; 148(3):615-24. PMC: 2174802. DOI: 10.1083/jcb.148.3.615. View

19.

Thrailkill K, Quarles L, Nagase H, Suzuki K, Serra D, Fowlkes J . Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. Endocrinology. 1995; 136(8):3527-33. DOI: 10.1210/endo.136.8.7543045. View

20.

Papathoma A, Petraki C, Grigorakis A, Papakonstantinou H, Karavana V, Stefanakis S . Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res. 2000; 20(3B):2009-13. View